Replies to post #154358 on Biotech Values

[mcbio]

How long do you expect this Phase II to take?

If it's like the prior trial, I would assume at least a couple of years. It will be interesting to at some point get some more specifics on the plan here. You would think AZN wouldn't have run the small trial of the planned P3 formulation if they didn't plan on moving to P3 shortly; perhaps AZN will push into P3 in other indications beyond KRAS NSCLC shortly (ocular? ovarian?) while they try and find a more tolerable regimen for KRAS NSCLC. I'm just going to be conservative and assume that the whole selumetinib program is delayed here though.